Jul 13, 2026 07:30AM
Jul 13, 2026 07:30AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM
May 28, 2026 04:01PM
May 7, 2026 04:01PM
Apr 30, 2026 04:01PM Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Apr 8, 2026 04:01PM
Apr 8, 2026 09:15AM
Apr 7, 2026 04:01PM
Apr 7, 2026 04:01PM
Mar 20, 2026 06:58AM
Mar 4, 2026 05:05PM
Feb 24, 2026 04:01PM Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Feb 11, 2026 07:30AM
Feb 11, 2026 07:30AM
Feb 4, 2026 04:01PM
Jan 12, 2026 07:45AM
Jan 11, 2026 02:00PM
Jan 11, 2026 02:00PM
Jan 5, 2026 04:34AM Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy
Dec 5, 2025 09:01AM
Dec 5, 2025 09:00AM
Dec 5, 2025 09:00AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 4, 2025 04:01PM
Oct 20, 2025 07:30AM Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
Oct 13, 2025 01:34PM
Oct 9, 2025 04:31PM
Oct 9, 2025 04:30PM
Oct 9, 2025 04:30PM
Sep 2, 2025 07:03AM
Sep 2, 2025 07:01AM
Sep 2, 2025 07:00AM Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Sep 2, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 18, 2025 05:11AM
Aug 12, 2025 04:01PM
Aug 11, 2025 07:00AM Stoke Therapeutics and BIOGEN begin phase 3 trial for rare epilepsy drug
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Jul 18, 2025 02:02AM
Jul 14, 2025 06:57AM
Jul 10, 2025 07:00AM
Jul 10, 2025 07:00AM Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Cong
May 13, 2025 07:00AM

325,892 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All